Literature DB >> 17704614

Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases.

Yoshiya Tanaka1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17704614     DOI： 10.2169/internalmedicine.46.1914

Source DB:  PubMed          Journal:  Intern Med        ISSN： 0918-2918            Impact factor:   1.271


× No keyword cloud information.
  2 in total

1.  B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis.

Authors:  Joseph M Tuscano; Jacob Sands
Journal:  Biologics       Date:  2009-07-13

2.  Long-term Successful Treatment of Rituximab for Steroid-resistant Minimal Change Nephrotic Syndrome and Idiopathic Thrombocytopenic Purpura.

Authors:  Mana Nishikawa; Noriaki Shimada; Tomohiro Kawazoe; Ryo Sawaki; Haruka Ikuta; Motoko Kanzaki; Kosuke Fukuoka; Masaki Fukushima; Kenichiro Asano
Journal:  Intern Med       Date:  2019-12-20       Impact factor: 1.271
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.